0001654954-20-003352.txt : 20200327 0001654954-20-003352.hdr.sgml : 20200327 20200326195556 ACCESSION NUMBER: 0001654954-20-003352 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200327 DATE AS OF CHANGE: 20200326 EFFECTIVENESS DATE: 20200327 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TENAX THERAPEUTICS, INC. CENTRAL INDEX KEY: 0000034956 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 262593535 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-363770 FILM NUMBER: 20747560 BUSINESS ADDRESS: STREET 1: ONE COPLEY PARKWAY STREET 2: SUITE 490 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919-806-4414 MAIL ADDRESS: STREET 1: ONE COPLEY PARKWAY STREET 2: SUITE 490 CITY: MORRISVILLE STATE: NC ZIP: 27560 FORMER COMPANY: FORMER CONFORMED NAME: OXYGEN BIOTHERAPEUTICS, INC. DATE OF NAME CHANGE: 20080703 FORMER COMPANY: FORMER CONFORMED NAME: SYNTHETIC BLOOD INTERNATIONAL INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: SINEQUANON CORP DATE OF NAME CHANGE: 19901219 D 1 primary_doc.xml X0708 D LIVE 0000034956 TENAX THERAPEUTICS, INC. ONE COPLEY PARKWAY Suite 490 MORRISVILLE NC NORTH CAROLINA 27560 (919) 855-2100 DELAWARE OXYGEN BIOTHERAPEUTICS, INC. SYNTHETIC BLOOD INTERNATIONAL INC SINEQUANON CORP Corporation true Michael B. Jebsen ONE Copley Parkway Suite 490 Morrisville NC NORTH CAROLINA 27560 Executive Officer Ronald R. Blanck ONE Copley Parkway Suite 490 Morrisville NC NORTH CAROLINA 27560 Director Gregory Pepin ONE Copley Parkway Suite 490 Morrisville NC NORTH CAROLINA 27560 Director James Mitchum ONE Copley Parkway Suite 490 Morrisville NC NORTH CAROLINA 27560 Director Chris A. Rallis ONE Copley Parkway Suite 490 Morrisville NC NORTH CAROLINA 27560 Director Gerald Proehl ONE Copley Parkway Suite 490 Morrisville NC NORTH CAROLINA 27560 Director Anthony DiTonno ONE Copley Parkway Suite 490 Morrisville NC NORTH CAROLINA 27560 Director Executive Officer Pharmaceuticals Decline to Disclose 06b false 2020-03-13 false true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 Park Avenue 3rd Floor New York NY NEW YORK 10022 AK ALASKA AL ALABAMA AR ARKANSAS AZ ARIZONA CA CALIFORNIA CO COLORADO CT CONNECTICUT DC DISTRICT OF COLUMBIA DE DELAWARE FL FLORIDA GA GEORGIA HI HAWAII IA IOWA ID IDAHO IL ILLINOIS IN INDIANA KS KANSAS KY KENTUCKY LA LOUISIANA MA MASSACHUSETTS MD MARYLAND ME MAINE MI MICHIGAN MN MINNESOTA MO MISSOURI MS MISSISSIPPI MT MONTANA NC NORTH CAROLINA ND NORTH DAKOTA NE NEBRASKA NH NEW HAMPSHIRE NJ NEW JERSEY NM NEW MEXICO NV NEVADA NY NEW YORK OH OHIO OK OKLAHOMA OR OREGON PA PENNSYLVANIA PR PUERTO RICO RI RHODE ISLAND SC SOUTH CAROLINA SD SOUTH DAKOTA TN TENNESSEE TX TEXAS UT UTAH VA VIRGINIA VT VERMONT WA WASHINGTON WI WISCONSIN WV WEST VIRGINIA WY WYOMING false 317167 317167 0 The amount sold reflects the purchase amount of the warrant issued to the investor and the warrant issued to H.C. Wainwright & Co., LLC, the placement agent of the private placement. false 1 206000 true 0 In connection with the registered direct offering concurrent with the private placement, the Placement agent received $206,000 for fees and a warrant to purchase up to 177,023 shares of common stock exercisable at an exercise price of $1.4564 per share. 0 A portion of the proceeds may be used for general corporate purposes, including to pay salaries of some related persons listed in Item 3. Tenax Therapeutics, Inc. /s/ Michael Jebsen Michael B. Jebsen President and Chief Financial Officer 2020-03-26